Start-up aims to harness the natural powers of cancer survivors to cure this life-threatening disease

Cure51 raises a €15 million seed round

09-Apr-2024
Computer-generated image

Symbolic image

Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

The funding received will enable Cure51 to build a unique cohort, exploring the molecular processes by which certain cancer patients survive for very extended periods of time despite having highly aggressive forms of the disease. The company seeks to unlock these mechanisms to enable every patient to become an exceptional survivor with new insights for precision medicine and drug target discovery. Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.

"This funding marks a pivotal moment in Cure51's journey, but more importantly, in the path towards curing cancer," says Nicolas Wolikow, Co-founder, and Chief Executive Officer of Cure51. "With this support, we are on our way to unlocking survival mechanisms and ultimately, saving countless lives,” adds Simon Istolainen, Cure51 Co-founder and Chief Strategy and Scientific Network Officer.

"Looking at ‘mechanisms of exceptional survival’ is not a new concept, but Cure51 has taken this to a whole new level in terms of the scale of the endeavor plus leveraging the latest in analytical techniques," said Simon Turner, Partner at Sofinnova Partners. "Cure51's strong clinical network and ambitious team make this an investment we’re thrilled to support."

“Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients,” notes Joanna Soroka, PhD, Principal at Hitachi Ventures GmbH.

Cure51 was founded in March 2022 by Nicolas Wolikow and Simon Istolainen, with input and support from Okwin co-founder Thomas Clozel, alongside seasoned entrepreneurs and five world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany), Milan - Italy), the Instituto Europeo di Oncologia (IEO - Milan, Italy) and Vall d'Hebron (VHIO, Barcelona - Spain). The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer. Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Other news from the department business & finance

Most read news

More news from our other portals

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

Last viewed contents

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

VTU Group appoints Liam O'Neil as new CEO

VTU Group appoints Liam O'Neil as new CEO

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026

Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management

Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management

Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany

Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany

Herz- und Diabeteszentrum Nordrhein-Westfalen (Universitätsklinik der Ruhr-Universität Bochum) - Bad Oeynhausen, Germany

Lead Discovery Center GmbH - Dortmund, Germany

Lead Discovery Center GmbH - Dortmund, Germany